RxDoctor Payments Data

Hussein Yamani, MD

Interventional Cardiology · Conroe, TXNPI 1003007204

Payments from drug & device makers

$29,712in general payments, 2019–2025

Across 633 payments — averaging $46.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
  • Medtronic$2K
  • Novartis$2K
  • Amgen$2K
  • Abbott$1K
  • Cardiovascular Systems Inc.$740
  • plus $5K from 30 others

What the payments were for

  • Speaking & faculty fees$16,25055%
  • Food & beverage$13,44845%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,712 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$469,859
Medicare patients
698
Services billed
4,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$426,897
XareltoRivaroxaban150$149,836
EntrestoSacubitril/Valsartan94$103,915
Repatha SureclickEvolocumab125$89,840
BrilintaTicagrelor36$26,688
Praluent PenAlirocumab17$15,560
Repatha SyringeEvolocumab16$8,523
Ranolazine ErRanolazine79$6,963
Metoprolol Succinate534$6,110
Valsartan277$5,796
Icosapent Ethyl11$5,366
NexletolBempedoic Acid11$5,045
Nifedipine ErNifedipine205$4,264
ClopidogrelClopidogrel Bisulfate404$3,896
Nebivolol Hcl63$3,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$228$426,897446 claims
Johnson & JohnsonXarelto$549$149,836150 claims
NovartisEntresto$2,061$103,91594 claims
AstraZenecaBrilinta$202$26,68836 claims
Esperion Therapeutics, Inc.Nexletol$297$5,04511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →